Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.

摘要: Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment There is extensive evidence from molecular and genomic analysis of human cancers that PI (phosphoinositide 3-kinase)-Akt/PKB (protein kinase B) deregulated in malignant progression. Furthermore, causal involvement supported by gene-knockout mouse models. Prototype inhibitors show anticancer activity vitro vivo animal The recent development isoform-selective shows considerable promise treatment.